Tranexamic Acid Access For All Mothers With Bleeding After Childbirth

Tranexamic acid (TXA) can stop women from bleeding to death after childbirth. However, health systems in low- and middle-income countries (LMICs) face critical barriers to ensure equitable access to this lifesaving drug. Although TXA is widely available and recommended for postpartum haemorrhage (PPH) by the WHO, the need to administer it intravenously means that clinics without the infrastructure or trained staff cannot currently provide this life-saving medicine; greatly limiting its potential. The I’M WOMAN Trial is part of the TRANSFORM project, funded by Unitaid.

The project aims to expand equitable access to TXA through three workstreams:

Evidence generation

The I'M WOMAN trial will provide evidence on the safety and efficacy of intramuscular TXA.

Enabling environment

We will engage stakeholders to generate demand and raise awareness about TXA and PPH

Supply side

We will create an information repository on TXA manufacturers, products and policies.

The TRANFORM project supports the Sustainable Development Goal to reduce the global maternal mortality rate to fewer than 70 per 100,000 live births. Collectively with the other projects in Unitaid’s PPH portfolio, the TRANSFORM project will serve to reduce PPH-related deaths, which disproportionately affect women in LMICs, especially those who lack access to quality care due to poverty, geography, or cultural barriers. Nearly all maternal deaths from bleeding after childbirth occur in LMICs, mostly in sub-Saharan Africa and South Asia (80% of all deaths)